Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 12/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11610638 | 0.81 | NR1H3 (0.54) | MLYCDNR1H3NR1H2NOTUMRORC | |
| SCHEMBL3626992 | 0.80 | NR1H3 (0.42) | MLYCDNR1H3NR1H2NOTUMRORC | |
| SCHEMBL3626460 | 0.78 | ALDH1A1 (0.46) | MLYCDNR1H3NR1H2RORCALDH1A1 | |
| SCHEMBL3624457 | 0.78 | RORC (0.45) | MLYCDNR1H3NR1H2RORCNR1I2 | |
| SCHEMBL3626261 | 0.75 | RORC (0.53) | MLYCDNR1H3NR1H2NOTUMRORC | |
| SCHEMBL3623987 | 0.73 | NOTUM (0.45) | NR1H3NR1H2NOTUMRORCALDH1A1 | |
| SCHEMBL26763830 | 0.71 | NOTUM (0.61) | NOTUMALDH1A1 | |
| SCHEMBL3619548 | 0.70 | NR1H3 (0.56) | NR1H3NR1H2NOTUMRORCNR1I2 | |
| SCHEMBL3626532 | 0.70 | NR1H3 (0.56) | NR1H3NR1H2NOTUMRORCNR1I2 | |
| SCHEMBL3619551 | 0.70 | NR1H3 (0.56) | NR1H3NR1H2NOTUMRORCNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2007050425-A2 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | MLYCD 3385/4885NR1H3 2/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.